Minnesota House Approves Psilocybin Therapy Program for PTSD, Depression, and Addiction

The Minnesota House of Representatives has approved a groundbreaking pilot program to legalize psilocybin-assisted therapy for adults 21 and older, positioning the state to become the fourth in the nation to authorize supervised psychedelic treatment. The measure passed with broad bipartisan support on May 8, 2026, by a vote of 114-15, reflecting growing political consensus around emerging mental health treatments that have shown promise for conditions long resistant to conventional interventions.

The psilocybin provision was added as an amendment to broader health and human services legislation, drawing on recommendations from a state task force that spent months studying the therapeutic potential of psychedelic compounds. If the Senate concurs and Governor Tim Walz signs the bill into law, Minnesota will join Colorado, Oregon, and New Mexico in creating regulated frameworks for psilocybin therapy—though each state's approach differs in significant ways.

A Conservative Entry Into Psychedelic Medicine

The Minnesota program is deliberately structured as a limited pilot, open to just 1,000 participants with qualifying medical conditions. Eligible diagnoses include post-traumatic stress disorder, treatment-resistant depression, chronic pain, and notably, substance use disorder—a condition that has seen devastating mortality rates across the state and nation.

"This program is a very conservative, slow entrance into this new area of psychedelic medicine," said Representative Andy Smith, the Rochester Democrat who sponsored both the amendment and an earlier standalone bill. Smith emphasized that the framework prioritizes safety and oversight, with the state's Office of Cannabis Management serving as the regulatory authority responsible for licensing facilitators, approving treatment centers, and evaluating program outcomes.

The supervised model requires that psilocybin sessions occur in regulated clinical settings with trained guides present throughout the experience. This approach mirrors the protocols used in clinical trials at institutions like Johns Hopkins University, where research has demonstrated that psilocybin can produce lasting improvements in depression, anxiety, and alcohol use disorder when combined with preparatory and integrative psychotherapy.

Federal Tailwinds

The Minnesota vote comes just weeks after President Donald Trump signed an executive order directing federal agencies to accelerate research into psychedelic therapies and expand patient access. The order makes $50 million available for state-level research programs, creating a rare opportunity for early-adopting states to secure federal funding for their initiatives.

Republican supporters of the Minnesota bill explicitly cited this federal shift as a key rationale for moving forward now. Representative Max Rymer, a Republican from North Branch, noted that the Trump administration's openness to psychedelic research "buoys" the state program and could help Minnesota compete for research dollars that might otherwise flow elsewhere.

"Many states are in no way ready to utilize that money," said Representative Nolan West, another Republican backing the measure. "So by being early, we can have a program that will help many people with severe conditions, and we'll have it paid for by the federal government."

This bipartisan alignment around accessing federal resources highlights how quickly the politics of psychedelic therapy have evolved. Where such measures might have faced unified opposition just a few years ago, lawmakers from both parties now see therapeutic potential, economic opportunity, and a chance to address constituent needs that traditional treatments have failed to meet.

Veterans and Trauma Survivors

The legislative debate featured powerful testimony from veterans and trauma survivors who described life-changing benefits from psilocybin therapy accessed through underground networks or out-of-state programs. These personal accounts appeared to resonate across party lines, with multiple Republican lawmakers citing veteran experiences as decisive factors in their support.

"The testimony that we heard firsthand, from especially a lot of our veterans, was that this was life-changing," Rymer said during floor debate. "The way that I look at this amendment is it creates an offering for people to not get hooked, necessarily, into drugs on an ongoing basis, but actually use a therapeutic like this to almost rewire their brain."

Research from Johns Hopkins and other institutions supports these anecdotal reports. Studies have found that psilocybin-assisted therapy can produce rapid, sustained reductions in PTSD symptoms, with some participants reporting significant improvement after just one or two sessions. For veterans who have exhausted conventional treatments, these findings represent a potential lifeline.

The inclusion of substance use disorder among qualifying conditions reflects mounting evidence that psychedelics may help interrupt addictive patterns. Clinical trials have shown promising results for both alcohol and tobacco dependence, with psilocybin appearing to facilitate behavior change by disrupting rigid thought patterns and enhancing psychological flexibility.

The Legislative Path Forward

While the House vote represents significant progress, the bill still faces hurdles before becoming law. The Minnesota Senate passed its own version of the broader health legislation without the psilocybin provisions, meaning the two chambers must reconcile their differences before the legislative session ends on May 18.

If the final bill reaches Governor Walz's desk, Minnesota would establish a timeline for program implementation that would likely see the first legal psilocybin sessions occur in 2027 or 2028, depending on how quickly regulators can develop licensing standards and approve treatment facilities.

The legislation also includes a directive for the Office of Cannabis Management to seek federal research funds, potentially positioning Minnesota as a hub for psychedelic science. With Johns Hopkins, NYU, and other major research institutions already conducting FDA-approved trials, state-level programs could generate valuable real-world data on how these therapies perform outside tightly controlled clinical settings.

A Cautious Approach

Minnesota's conservative pilot structure reflects lessons learned from earlier-adopting states. Oregon's broader psilocybin program, approved by voters in 2020, has faced implementation challenges including high costs that put treatment out of reach for many potential beneficiaries. By limiting participation to 1,000 people initially, Minnesota hopes to work out regulatory kinks while gathering evidence on safety and efficacy.

The qualifying conditions list also suggests a focus on populations with the most to gain—and the fewest existing options. Treatment-resistant depression, PTSD, and substance use disorder all share high mortality burdens and limited response rates to conventional pharmacotherapy. For these patients, psilocybin represents not a first-line treatment but a potential intervention when other approaches have failed.

As psychedelic therapy moves from countercultural curiosity to mainstream medical consideration, Minnesota's approach may offer a template for other states seeking to balance access with oversight. The bipartisan vote suggests that when framed as a treatment option for veterans and others suffering from severe mental health conditions, psychedelic policy can transcend traditional political divides—particularly when federal funding helps sweeten the deal.

The coming weeks will determine whether the Senate agrees to include psilocybin provisions in the final health bill. For thousands of Minnesotans struggling with conditions that have resisted conventional treatment, the outcome could determine whether relief remains accessible only through underground channels or becomes available through regulated, supervised therapeutic settings.